Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Non-Interest Income (2016 - 2022)

BioRestorative Therapies (BRTX) has disclosed Non-Interest Income for 12 consecutive years, with $245.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Non-Interest Income fell 96.06% year-over-year to $245.0, compared with a TTM value of $245.0 through Mar 2023, down 97.59%, and an annual FY2021 reading of $12290.0, down 56.54% over the prior year.
  • Non-Interest Income was $245.0 for Q2 2022 at BioRestorative Therapies, down from $469.0 in the prior quarter.
  • Across five years, Non-Interest Income topped out at $156179.0 in Q3 2019 and bottomed at $150.0 in Q3 2020.
  • Average Non-Interest Income over 5 years is $42045.2, with a median of $15837.0 recorded in 2019.
  • The sharpest move saw Non-Interest Income surged 2120.39% in 2018, then crashed 99.9% in 2020.
  • Year by year, Non-Interest Income stood at $138489.0 in 2018, then tumbled by 70.82% to $40415.0 in 2019, then crashed by 99.63% to $150.0 in 2020, then skyrocketed by 2013.33% to $3170.0 in 2021, then plummeted by 92.27% to $245.0 in 2022.
  • Business Quant data shows Non-Interest Income for BRTX at $245.0 in Q2 2022, $469.0 in Q1 2022, and $3170.0 in Q4 2021.